Infliximab in Severe Ulcerative Colitis Delays and Prevents Early Colectomy

Infliximab in Severe Ulcerative Colitis Delays and Prevents Early Colectomy
According to a study published in the journal Clinical Gastroenterology and Hepatology, the use of infliximab in patients with acute severe ulcerative colitis reduces the need for early colectomy. In the study titled “An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis,” David Gibson from the Centre for Colorectal Diseaseat St Vincent’s University Hospital and School of Medicine and Medical Science in Ireland along with colleagues retrospectively evaluated 50 patients who were given two regimens of infliximab for steroid-refractory acute severe ulcerative colitis (ASUC). The researchers divided the patients in two groups: the first group of 35 patients received a regimen of standard infliximab dosing at 0, 2, and 6 weeks and then every 8 weeks. The second group of 15 patients received an accelerated regimen and then three induction doses of infliximab for 24 days. The researchers then compared the rates of colectomy between the two groups throughout induction and after the follow-ups. Results revealed that both groups had similar baseline levels of C-reactive protein, albumin, or hemoglob
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *